Sevigny Jeffrey 4

What Happened

• Jeffrey Sevigny, Chief Medical Officer of Rapport Therapeutics (RAPP), was granted 130,000 derivative shares (reported as an "A" grant) on 2026-02-02. The filing reports an acquisition price of $0.00 for the award (total reported cash exchanged = $0). This is a compensation award (not a market purchase or sale).

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (filed within the typical 2-business-day window).
• Reported amount: 130,000 derivative shares granted at $0.00 (transaction code A).
• Vesting: The shares underlying this option will vest and become exercisable in 48 equal monthly installments beginning January 1, 2026, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided Form 4.
• Filing timeliness: Timely (no late filing indicated).

Context

• This is a grant of a derivative award (an option-style award per the footnote) tied to service-based vesting; it does not represent an immediate purchase of common stock or an immediate sale. Such awards are common executive compensation and do not, by themselves, indicate insider buying or selling intent. Investors who want more detail (exercise price, potential dilution, or fair value) should review the company’s proxy statements or related compensation disclosures.